Newsroom press releases

30/11/21 - 19:10

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)

Products Molecular

29/11/21 - 7:06

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)

Products Immunodiagnostic

23/11/21 - 7:10

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)

Products Immunodiagnostic

18/09/21 - 8:16

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)

Products Molecular

15/06/21 - 6:56

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)

Products Immunodiagnostic

25/05/21 - 7:03

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)

Products Immunodiagnostic

21/05/21 - 7:02

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)

Products Molecular

20/05/21 - 8:27

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)

Products Immunodiagnostic

21/04/21 - 7:02

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)

Products Immunodiagnostic

20/04/21 - 18:58

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)

Products Immunodiagnostic

30/03/21 - 7:01

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)

Products Immunodiagnostic

29/03/21 - 7:02

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)

Products Immunodiagnostic

23/02/21 - 6:11

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)

Products Immunodiagnostic

11/01/21 - 18:43

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)

Products Immunodiagnostic

21/12/18 - 11:30

DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)

Products Molecular

19/11/18 - 15:00

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)

Products Molecular

17/10/18 - 11:51

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)

Products Molecular

12/10/18 - 11:47

DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)

Products Molecular

17/09/18 - 11:28

DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)

Products Immunodiagnostic

27/07/18 - 12:00

DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)

Products Immunodiagnostic

12/06/18 - 14:15

DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)

Products Molecular

05/04/18 - 12:00

DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)

Products Immunodiagnostic

28/03/18 - 18:45

DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)

Products Molecular